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Exercise and sports activities are crucial for individuals with diabetes. Diabetic
patients are often referred to sports clinics for cardiopulmonary exercise testing to
evaluate physical capacity, exercise-related symptoms, or to obtain medical clearance.
While there is an abundance of literature on cardiopulmonary testing, practical
recommendations for exercise physiologists and sports clinic specialists performing
exercise testing for this specific population are lacking. The goal of this report is to
provide a practical framework to understand, prepare, and perform exercise testing in
patients with diabetes, maximizing exercise physiology outcomes, diagnostic value, and
ensuring safety.
Keywords: cardiopulmonary exercise testing, exercise-induced hypoglycemia, exercise test preparation, insulin,
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INTRODUCTION
Cardiopulmonary exercise testing (CPET) is commonly performed in sports medicine (Acsm,
2013; Fletcher et al., 2013). In this particular setting, the goals may differ from CPET performed
in cardiology or pneumology clinics (Guazzi et al., 2012). Indications for an exercise capacity
evaluation in sports medicine clinics are habitually related to training prescription, to identify
causes in performance limitation, or to obtain medical clearance (Riebe et al., 2015). As for the
general population, regular physical activity is recommended for individuals with diabetes for
overall health (Colberg et al., 2016) as well as to promote better glycemic control (Colberg, 2017).
Recommendations vary depending on the type of diabetes and specific individual characteristics
such as treatment, habitual training load, and preexisting complications (Colberg et al., 2010, 2016).
For each individual, specific and different precautions are necessary before, during, or after physical
activity (Younk et al., 2011; Colberg et al., 2016), particularly at high intensity exercise, which is the
case during a maximal stress test. This paper is addressed to sports medicine practitioners and
exercise physiologists with the goal of helping them prepare and perform optimal exercise testing,
maximizing diagnostic value, and ensuring safety.
REFERRAL
Individuals with diabetes are often referred to sports medicine clinics with the same objectives
as non-diabetics: to evaluate physical capacity, for training prescription, to evaluate exercise-
related symptoms, and to obtain medical clearance for specific events or high intensity
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training (Colberg et al., 2016). Diabetologists and diabetes patient
educators (American Diabetes Association, 2019a) may also
refer their athletic patients to understand glycemic responses
to exercise (hypo- or hyperglycemia) or unexplained changes
in performance, or simply to increase patient’s education and
individual competence, which includes specific dietary and
medication adaptations required for different physical activities
of various intensities (American Diabetes Association, 2019a).
Athletic trainers may want to use CPET to target with precision
training heart rate ranges in diabetic athletes given the fact that
recent research has shown systematic overestimation of target
heart rate in diabetic individuals when applying computation
percentages of maximum heart rate or heart rate reserve
compared to objective individual markers obtained during a
CPET (Moser et al., 2018b). Like with any other exercise testing,
the referral purpose should be clear in advance. If the indication
for the test is not clear, further information should be obtained by
the referring provider.
Guidelines whether or not to perform systematic CPET for
diabetic individuals vary according to region and professional
associations. In the last recommendations from the American
Heart Association (Fletcher et al., 2013), exercise testing is
proposed for screening coronary artery disease in asymptomatic
individuals who have diabetes based on the fact that diabetes
is itself a risk for coronary artery disease. The updated
recommendations from the American College of Sports Medicine
(Riebe et al., 2015) state that preparticipation health screening
should be decided on the basis of the individual’s current physical
activity level, the desired exercise intensity, the presence of signs
and symptoms, and his medical history (including the presence
of diabetes). Both of these recommendations are discussed
in the recent position statement from the American Diabetes
Association (Colberg et al., 2016), which points to the fact that
there is no evidence suggesting that any screening protocol
beyond usual diabetes care reduces the risk of exercise-induced
adverse events in asymptomatic individuals with diabetes. The
authors conclude that pre-exercise medical clearance is not
necessary for asymptomatic individuals receiving diabetes care
who wish to begin low- or moderate-intensity physical activity
not exceeding the demands of brisk walking or everyday living.
Individuals who plan to increase their exercise intensity or
who meet higher risk criteria, such as their age, diabetes
duration, and the presence of additional cardiovascular disease
risk factors, may benefit from referral for a medical checkup
and possible exercise stress test before starting such activities
(Colberg et al., 2010, 2016).
CONTRAINDICATIONS AND SCREENING
The screening procedure and content is the same as for non-
diabetic patients (Corrado et al., 2005; Borjesson et al., 2011;
Fletcher et al., 2013) with additional specific questions in the
history, clinical exam, and context that need to be taken
into account in the decision to perform or not a CPET.
Absolute and relative contraindications to exercise testing due to
cardiovascular conditions (acute myocardial infarction, unstable
angina, active endocarditis, etc.) or uncontrolled hypertension
are the same for all individuals (Fletcher et al., 2013). Absolute
contraindications specific to individuals with diabetes are a poor
glycemic control, particularly with high and low excursions that
place the patient at risk for a severe hypo- or hyperglycemia,
and severe retinopathy that increases the risk of retinal
detachment and vitreous hemorrhage during intense exercise
(Colberg et al., 2010). All other contraindications are relative.
Nephropathy is not a contraindication per se, although
in situation of end-renal disease patients in dialyses should
be monitored for blood electrolytes (Colberg et al., 2010).
As vigorous exercise may lead to false positive readings of
microalbuminuria, it is advised not to perform urine check-up
on the day after a maximal exercise test. Peripheral neuropathy
is not a contraindication to perform exercise testing, but few
considerations may need to be taken into account (Colberg
et al., 2010). Weight-bearing exercise should be avoided in
unhealed ulcers or amputation sites (Colberg et al., 2010).
Appropriate footwear for local foot deformity may need
adaptations of the exercise test setting. Autonomic neuropathy
is a cause of chronotropic incompetence with an attenuated
heart rate response to exercise, which will impact termination
criteria based on heart rate reserve or theoretical maximal
heart rate (Colberg et al., 2010). Autonomic neuropathy may
also lead to postural hypotension, alter thermoregulation, and
delay gastric emptying, which predisposes to hypoglycemia
given unpredictable carbohydrate delivery (American Diabetes
Association, 2010, 2019c). If no contraindications are evidenced
through history and physical examination, the test has to be
prepared carefully in advance to avoid complications.
SUBJECT PREPARATION
High intensity exercise in diabetes is metabolically safe if
planned correctly (Gawrecki et al., 2017). Planning must be
done in the days previous to the CPET. The goal is to be
in ideal conditions for the CPET, allowing the patient to
perform to maximal capacity, reaching informative exercise and
metabolic adaptations, avoiding counter-regulatory mechanisms,
and without having to stop the test due to safety risks.
Preparedness includes the avoidance of hypoglycemia, which
depends on diabetes medication (Table 1). Exercise-induced
hypoglycemia is common in diabetics using insulin or insulin
secretagogues (i.e., glinides and sulfonylureas) (Shahar and
Hamdy, 2015). Recently, many oral treatments for diabetes
have been commercialized with other proprieties than just
glycemic control, like kidney or cardiac protection (e.g.,
SGLT2 inhibitors, GLP1 receptor agonists) (American Diabetes
Association, 2019b). Most of these medications have low risk or
even no risk of hypoglycemia (Hinnen, 2017; Yang et al., 2017).
Identifying the type of medication used is critical to take into
account to prepare the CPET.
In patients treated with insulin, hypoglycemia can happen
during, immediately after, or many hours after acute exercise,
such as during the following night (Colberg et al., 2016). The
risk of hypoglycemia is minimized through multiple strategies
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TABLE 1 | Risk of exercise-induced hypoglycemia depends on the type of diabetes medication.
Class and molecules Risk of hypoglycemia CPET precaution and preparation
Biguanide Low - No preparation required.
Metformine - Measures of glycemia before and after CPET for educational purposes.
DPP4 inhibitors (also called gliptins) - Fast-acting oral glucose available.
Sitagliptin, linaglitpin, saxagliptin, vildagliptin, gemigliptin,
anagliptin, teneligliptin, alogliptin, trelaglptin, omarigliptin,
evogliptin, gosoglptin
SGLT2 inhibitors (also called gliflozins)
Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin,
ipragliflozin, luseogliflozin, tofogliflozin, sotagliflozin∗
GLP1 receptor agonists (also called incretin mimetics)
Exenatide, liraglutide, lixisenatide, dulaglutide, albiglutide,
semaglutide
Thiazolinediones (also called Glitazones)
Pioglitazone, rosiglitazone, lobeglitazone
Glinides (also called Meglitinides) High - Preparation required.
Repaglinide, nateglinide, mitiglinide - Repeated measures of glycemia before, during and after CPET for safety
purposes.
Sulfonylureas - Fast-acting oral glucose available.
Chlorpropamide, gliclazide, glimepiride, glibenclamide
(= glyburide), glipizide, tolbutamide, tolazamide
Insulin and insulin analogs
NPH, aspart, lispro, glulisine, detemir, degludec, glargine
DPP4, dipeptidyl peptidase 4; SGLT2, sodium–glucose transport protein 2; GLP1, glucagon-like peptide-1; NPH, neutral protamine hagedorn. ∗Sotagliflozin is a dual
SGLT1/SGLT2 inhibitor. Remarks: A low risk compound in combination with a high-risk medication may further increase the risk. New compounds are tested and
approved regularly. Please use caution if a specific molecule is not listed.
including reductions of daily basal insulin dose, reductions
of prandial insulin bolus, modification of carbohydrate intake
before or during the test (fast acting glucose) or in the meals
following the test (complex carbohydrates), inclusion of snacks,
and regular glucose checks (Colberg et al., 2016). These strategies
are based on individual experiences, such as reducing the long-
lasting insulin the night previous to the test, or eating a pre-
test meal with specific content and timing, or removing the
insulin pump at a specific time before the test. These strategies
require advanced planning, preparation, and patient’s know-how.
Athletes with diabetes have usually an important knowledge of
their own glycemic profile and experience on how to adapt
their insulin-therapy or carbohydrate intake to specific exercise
durations, intensities, or settings, which is not the case for non-
regular exercisers or for patients who have a poor diabetes
education or no diabetes care team (Colberg et al., 2016;
American Diabetes Association, 2019b). Thus, depending on
exercise habits, experience, and diabetes management, we believe
that only a subset of diabetic athletes may not require medical
screening and preparation guidance before a CPET (Figure 1). As
a rule of thumb, any doubt or previous adverse effect of exercise
on glycemic control should motivate a medical evaluation to plan
and prepare accurately the stress test.
In patients at risk of hypoglycemia (Table 1), avoidance of
exercise-induced hypoglycemia is best achieved when glycemia
is between 8.3 and 13.9 mmol/L (150–250 mg/dL) at the start
of the test (Colberg et al., 2016). Thus, preparation includes
anticipating what happens in the last hours or days to get to
that specific range at the time of the test. A pre-test blood
glucose <5 mmol/L (<90 mg/dL) is a contraindication to the
test. The test should be postponed, as even a rapid correction
of glycemia will not impair counter-regulatory mechanisms to
kick in and impact normal physiological adaptations. A blood
glucose range between 5 and 8.3 mmol/L (90–150 mg/dL) is
not ideal, the patient should consume additional carbohydrates
before starting the test, in amounts depending on the dose
and type of insulin that was injected in the hours before
the test (between 15 and 30 g of fast acting carbohydrates),
thus delaying the start of the test until the desired glycemia
is obtained. As an antecedent hypoglycemia severely blunts
counter-regulatory responses to exercise, increasing the risk of
recurrent hypoglycemia, exercise testing should be avoided for
24 h after an episode of hypoglycemia (Galassetti et al., 2003).
On the hyperglycemia side, a pre-test glycemia between
13.9 and 19.4 mmol/L (250–350 mg/dL) is not a strict
contraindication to exercise if ketone bodies are absent (Colberg
et al., 2016). If ketosis is detected (>1.5 mmol/L), exercise
should be postponed, irrespective of glycemic level, as intense
exercise may exaggerate hyperglycemia and ketosis (American
Diabetes Association, 2010). Pre-test glycemia >19.4 mmol/L
(>350 mg/dL) is a contraindication to intense exercise. Although
reports indicate that maximal physical effort can lead to
metabolic decompensation, based on incorrect insulin dose
(Campbell et al., 2014), increased carbohydrate consumption
associated with the fear of hypoglycemia or catecholamine
response to intense exercise (Campbell et al., 2014), a recent
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FIGURE 1 | Screening and preparation flowchart for individuals with diabetes referred for a cardiopulmonary maximal exercise test. CPET, cardiopulmonary exercise
testing.
study has shown that if planned accurately intense exercise is safe
in insulin treated diabetics with hyperglycemia >16.6 mmol/L
(>300 mg/dL) occurring in 10% of patients while ketone
bodies were within reference range (Gawrecki et al., 2017).
Nevertheless, how these high glycemia influences physiological
outputs and reliance on data acquired during exercise testing
is not known and should be taken with caution if the test
is used for performance purposes and training prescription.
Exercise physiologists and patients should ponder to perform
the test in conditions that represent more accurately the athlete’s
common situation. At the contrary, if the test is performed to
understand glycemic excursions the information acquired with
the test may be useful.
Patients should monitor their blood glucose in the days before
the CPET and plan to reach the desired glycemic range at the time
of the appointment. This may require scheduling the CPET at a
moment that is easier to anticipate, such as in the mid-morning
or depending on the individual routine. Similarly to non-diabetic
individuals, no exercise should be performed before the CPET
and the subject should report to the clinic well hydrated with
his glucometer, plenty of glucose strips, glucose tablets or his/her
preferred fast acting glucose replacement.
To reach the desired glycemia range, two concurrent
approaches may be taken into account: therapy adaptation and
carbohydrate supplementation (American Diabetes Association,
2002). This is where the patients’ know-how is crucial (Dizon
et al., 2019). Insulin therapy is the only treatment that could
need an adaptation before CPET and depends on insulin regimen,
i.e., multiple daily injections or subcutaneous insulin infusion
(pump). Physical activity during CPET is of short duration, but
very intense, so basal long acting insulin injections are usually
not modified, but again this is unique to each individual and
the pharmacodynamics of the different insulins. For rapid acting
insulin injections, decreasing dose before or after the test may
be needed (Colberg et al., 2016; Riddell et al., 2017). With
continuous subcutaneous insulin therapy, basal insulin can be
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turned off before, during, and/or after the acute bout of exercise.
The basal insulin rate may need to be reduced at least 30 min
prior to the start of the exercise to allow time for receptor-
bound insulin to become inactivated (Kirk, 2009). For other
medications with a risk of hypoglycemia (sulfonylureas, glinides),
a modification of the dosage is not recommended, but similar to
insulin therapy, a particular attention after the test is necessary.
If previous exercise induced hypoglycemia has occurred with
secretagogues, decreasing dose on exercise days may reduce
hypoglycemia risk and thus may be recommended (Colberg et al.,
2016; Riddell et al., 2017). Recording meals content, insulin
dosage, and glycemia before and after the CPET, even during
the night, are usually very informative and allow using the CPET
results for educational purposes.
Carbohydrate supplementation is the other option to reach
the desired glycemic range before the test (Colberg et al., 2016;
Riddell et al., 2017). Guidelines recommend consuming 10 to
15 g of carbohydrate to prevent exercise-induced hypoglycemia,
but many studies illustrate that carbohydrate supplementations
must be individualized to the type of insulin, i.e., peak
insulin levels and duration of insulin action, as well as the
absorptive state (Francescato et al., 2004; Dube et al., 2005).
Here again, taking the time to discuss test preparation on
an individual base is important. Particularly getting to know
each individual carbohydrate supplementation habits, early
hypoglycemia symptoms and preferred glucose replacement
therapy are all important to take into account during the CPET.
EXERCISE TEST PROTOCOL AND
SUPERVISION
The test protocol should be selected according to the purpose
of testing and the individual patient, similarly to what is
done for non-diabetic individuals (Fletcher et al., 2013).
Medical supervision follows also the same guidelines as non-
diabetic individuals. Exercise testing should be performed
under the supervision of qualified health professionals
appropriately trained to administer exercise tests and advanced
cardiopulmonary resuscitation (Myers et al., 2009). Good
communication with the patient is crucial. Test supervisor
should know the patient’s specific hypoglycemia symptoms,
know how to interpret glycemia modifications during the
test, and correct an eventual hypoglycemia. The patient
should receive detailed explanations on the purpose of the
test, testing procedure, including end points and possible
complications if that was not performed during the screening
and preparation phase. Supplementary Table 1 provides an
example of CPET preparation and supervision form specific to
individuals with diabetes.
Measurements of blood glucose levels before, during the
exercise test, in the recovery period as well as several hours
after the test, are necessary in patients treated with insulin or
insulin secretagogues in order to avoid extreme excursions in
blood glucose levels (Colberg et al., 2016). Recording of capillary
glycemia can be performed alongside with other common
measurements such as lactate concentrations, RPE, etc. Capillary
glycemia is preferred over the use of subcutaneous continuous
glucose monitoring (CGM) for exercise testing as these are still
debated for their accuracy during exercise and due to the time
lag between the change of blood glucose and its detection by the
CGM (Iscoe et al., 2012; Kropff et al., 2015; Moser et al., 2016,
2019). If the patient has a CGM and is using it for his/her usual
exercise routine, the combination of CGM and capillary glycemia
during the CPET will be useful for education purposes, i.e., to
know the tendency and accuracy of the specific CGM device.
For clinical settings, real-time glycemia using a well-calibrated
strip glucometer is sufficient as the most important information
is the relative modification of glycemia. For research exercise
labs, the use of a more accurate and precise glucometer using
glucose oxidase technology, such as the YSI 2300 (Yellow Springs
Instruments Corp., Yellow Springs, OH, United States) coupling
the enzymatic assay with oxygen sensors, may be warranted
(Amati et al., 2014).
Carbohydrate replacement during and after exercise may help
prevent hypoglycemia although it will also impact gas collection
and thus impair the proper CPET outcomes. Oral fast acting
glucose should be available and ready to be used in the testing
room. To treat hypoglycemia (<4 mmol/L or <70 mg/dL) in
conscious individuals, 15 g of fast acting glucose should be given
orally and repeated if glycemia is still <4 mmol/L after 15–
20 min. For regular exercisers, the personnel may want to ask
them to bring their habitual fast acting glucose in order to follow
what they would do in a real situation.
Like in non-diabetic individuals beta-blockers are known to
blunt heart rate response to exercise and lower maximal exercise
capacity due to their chronotropic and inotropic negative effects
(Sigal et al., 1994). Here, it is also important to know that beta-
blockers are thought to induce hypoglycemia unawareness and
unresponsiveness, thus a particular attention needs to be brought
by the exercise physiologist in patients taking beta blockers
(White and Campbell, 2000).
INTERPRETATION AND TRAINING
ZONES
Interpretation of the CPET outcomes should be done as usual,
independently of the presence of diabetes or not (Balady et al.,
2010; Guazzi et al., 2012, 2016). Although the debate is still on,
studies suggest that highly trained individuals with diabetes can
achieve the same maximal cardiopulmonary exercise response as
similarly trained subjects without diabetes (Veves et al., 1997;
Baldi et al., 2010). These responses are reduced by poor glycemic
control despite the fact that training volumes and competition
levels are the same as the optimal control group (Baldi et al.,
2010). As it is very difficult to match subjects based on exercise
physiology outcomes, there are no studies to our knowledge
that were able to compare submaximal CPET outcomes in
diabetics and non-diabetics while at the same time being able
to control for training modalities or habitual physical activity.
Most of the studies conclude that poor glycemic control is
associated with reduced exercise performance in submaximal
intensities (Moser et al., 2017) and modify heart rate dynamics
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(Moser et al., 2018a). This is of importance for exercise
prescription. Submaximal thresholds measured during CPET
are valid and objective individual markers for patients with
diabetes, while using percentages of maximum values, maximum
heart rate, or oxygen uptake, are not sufficient to prescribe
exercise intensity individually as almost 63% of their diabetic
cohort presented atypical heart rate responses (Moser et al.,
2018b). Thus, prescribing by percentages of maximal heart
rate or heart rate range not based on individual thresholds
may push individuals with diabetes to exercise at too high
intensity, inducing different training effects than those desired
(Moser et al., 2018b).
CONCLUSION
Planned high intensity exercise in well-controlled diabetes is safe,
thus CPET too. Diabetes medication is not a contraindication
for CPET. A thorough screening is required and includes the
search of potential risks for hypoglycemia. The key aspect to
obtain valid data is planning to avoid glycemic excursions
in subjects with insulin therapy or insulin secretagogues. An
important aspect to take into account is that there is no “one size
fits all.” Preparing and performing a CPET with an individual
with diabetes includes taking into account individualities,
know-how, and past experiences. These recommendations
are also of interest in other forms of stress tests (e.g.,
stress electrocardiogram-EKG) without gas exchange analysis.
Following-up with the glycemic profile is also required after
the test for at least 24 h if the patient presents a risk
of hypoglycemia.
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Supplementary table 1, CPET in individuals with diabetes - preparation and report form 
 
 
Patient’s information 
 Name  Surname  Date  
Weight (kg)  Height (cm)  Sex  
Time  Sport    
Training frequency 
(x/week) 
 Training volume 
(h/week) 
   
Indications for 
CPET 
 
 
 
 
Drugs & 
treatments  
 
 
Test conditions 
Exercise mode [ ] Treadmill 
[ ] Ergocycle 
[ ] ………………… 
Protocol : [  ] stage 
[  ] ramp 
Rest : 
WU WR : 
WU duration: 
 
Stage duration: 
Start WR: 
Increment: 
 Flow volume loops [  ] yes 
[  ] no 
Mask size  
Temperature (C°)  Humidity (%)  
 
 
Barometric 
pressure (mmHg) 
 
Last cigarette or 
tobacco product 
 Caffeine - theine 
(last 12 hours) 
 
 
 
Alcohol (last 24 
hours) 
 
Previous exercise 
 Mode Duration Intensity 
Today    
24h    
48h    
Dietary 
supplements 
 Health issue (last 
14 days) 
 
 
 
Last food intake 
and time 
 
Musculoskeletal 
injury (last 6 
months) 
 
 
 
Other (sleep, 
travel,…) 
 
Test motivation 1 2 3 4 5 6 7 8 9 10 
Conditions specific to diabetic patients 
Screening done before the day of testing [  ] yes 
[  ] no 
Nephropathy [  ] yes 
[  ] no 
If yes, apply recommended precautions 
Peripheral neuropathy [  ] yes 
[  ] no 
Autonomic neuropathy [  ] yes 
[  ] no 
Blood glucose diary of previous 
days available 
[  ] yes 
[  ] no 
Diabetes 
 
[  ] Unstable 
[  ] Stable 
[  ] No recurrent hypoglycemia in the last 7 days 
[  ] No hypoglycemia < 3.0 mmo/l the last 12 hours 
[  ] No recurrent hyperglycemia > 14 mmol/l the last 7 days 
[  ] No hyperglycemia >19.5 mmo/l the last 12 hours 
Pre-test blood glucose [  ] <5 mmol/L (<90 mg/dL) – contraindication  
[  ] 5-8.3 mmol/l (90-150mg/dL) - consume additional carbohydrates, delay the test if insulin or insulin 
secretagogues 
[  ] 8.3-13.9 mmol/l (150-250mg/dL) 
[  ] 13.9 -19.4 mmol/l (250-350mg/dL) + ketosis <1.5mmol/L – not optimal for performance assessment 
[  ] 13.9 -19.4 mmol/l (250-350mg/dL) + ketosis >1.5mmol/L - contraindication 
[  ] 19.4 mmol/L (>350 mg/dL) -  contraindication 
Pre-test desired glycemic range 
reached  
[  ] yes 
[  ] no 
 
Report form: 
Stage Time 
WR 
 [W] 
[km·h-1] 
HR 
[bpm] 
RPE 
[6-20] 
[0-10] 
Lactate* 
[mmol·l-1] 
Glucose
* 
[mmol·l-1] 
[mg·dL-1] 
Cadence 
[rpm] 
[ppm]] 
Blood 
pressure          
[mmHg] 
 
SPO2 
[%] Other 
Rest           
WU           
1           
2           
3           
4           
5           
6           
7           
8           
9           
10           
11           
12           
13           
14           
15           
           
           
           
           
           
Exercise stop (time):        
Rec 
30’’ 
          
Rec 1’           
Rec 2’           
Rec 3’           
Rec 4’           
Rec 5’           
Rec 6’           
           
           
Test duration :  
Reasons for test 
abortion : 
 
 
Remarks :  
 
 
 
*Lactate and glucose measures to be adapted at different time points depending on the protocol used. 
WU=warm-up WR=work rate, HR=heart rate, RPE=rate of perceived exertion, SPO2=peripheral; capillary oxygen saturation, Rec=recovery. 
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